

**FUEHRING Stefan (ENTR)**

---

**From:** ENTR /F/2 PHARMACEUTICALS  
**Sent:** mardi 8 septembre 2009 15:09  
**To:** FUEHRING Stefan (ENTR)  
**Cc:** SALVADOR ROLDAN Rocio (ENTR)  
**Subject:** FW: Detailed Guidance for the Request for Authorisation of a Clinical Trial on a Medical Product for Human Use to the Competent Authorities, Notification of Substantial Amendments and Declaration of the End of the Trial (Draft Revision 3)

[A/21432](#)

---

From: Karen Real [mailto:kreal@realregulatory.ie]  
Sent: Tuesday, September 08, 2009 3:08 PM  
To: ENTR /F/2 PHARMACEUTICALS  
Subject: Re: Detailed Guidance for the Request for Authorisation of a Clinical Trial on a Medical Product for Human Use to the Competent Authorities, Notification of Substantial Amendments and Declaration of the End of the Trial (Draft Revision 3)

Dear Sir/Madam,

We, at Real Regulatory Ltd, have read with great interest the draft revised guidance for the conduct of clinical trials. We feel that this revised guidance will help clarify and create greater harmony for clinical trials among member states. We note the emphasis placed on the fact that the guidance is not the bare minimum and that countries cannot 'add-on' to these with their own, additional requirements. The re-structured guidance, along with specified references to more in-depth guidance is far more directed than the current version of the document, and overall is much more useable.

We have also read with interest the revised end of trial procedure and note the acknowledgement that it is not always possible to provide the clinical summary report within one year. This is in line with our own experience and we feel that this will reduce the pressure on industry to try and rush out these reports in order to maintain compliance.

One query we have was that whilst reading the consultation document, we noticed that the revised guidance no longer lists the inclusion of the labels for the IMP among the documents required for the initial CTA application submission. However, further on in this guidance document, (section 3.3.2) there is reference to the fact that minor changes to the labeling aren't necessary considered substantial. This later reference implies that perhaps the requirement for labels to be included in the initial CTA application has been omitted rather than consciously removed? We would recommend further clarification here. Furthermore, as the labeling requirements throughout Europe vary, we would request that more detailed clarification for clinical trial labels be provided.

We eagerly await finalisation of this guidance document.

Kind regards

**Karen Real**  
Director  
Real Regulatory

Tel +353 (0)1 885 1710 (Dublin)  
Tel +44 (0) 203 178 7140 (London)

6/10/2009

Fax +353 (0)1 882 9823  
Mob +353 (0)87 679 8791

---

This E-mail transmission may contain confidential or legally privileged information that is intended for the addressee only. E-mail communications are not necessarily secure and may be intercepted or altered after they are sent. Real Regulatory does not accept liability for any such alterations. Any views or opinions presented are solely those of the author and do not necessarily represent those of Real Regulatory. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or reliance upon the contents of this E-mail is strictly prohibited. If you have received this E-mail transmission in error, please notify the sender immediately, so that Real Regulatory may arrange for its proper delivery. Please then delete the message from your inbox. While steps have been taken to prevent computer viruses, we cannot guarantee that attachments are virus free and we would therefore advise that you make further checks as Real Regulatory are not liable to third parties for any damages resulting.

Real Regulatory Limited, Unit 9a, Plato Business Park, Damastown, Dublin 15, Republic of Ireland. Registered No 352250 Telephone + 353 1 885 1710 Fax + 353 1 885 1601 [www.realregulatory.ie](http://www.realregulatory.ie)

Real Regulatory Limited, Hudson House, 8 Tavistock Street, Covent Garden, London. WC2E 7PP United Kingdom. Registered No FC028563, Branch Number BR010159. Telephone + 44 203 178 7140 Fax + 44 203 178 4836 [www.realregulatory.co.uk](http://www.realregulatory.co.uk)